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Abstract
Babies born clinically Small- or Large-for-Gestational-Age (SGA or LGA; sex- and gesta-
tional age-adjusted birth weight (BW) <10th or >90th percentile, respectively), are at higher
risks of complications. SGA and LGA include babies who have experienced environment-
related growth-restriction or overgrowth, respectively, and babies who are heritably small or
large. However, the relative proportions within each group are unclear. We assessed the
extent to which common genetic variants underlying variation in birth weight influence the
probability of being SGA or LGA. We calculated independent fetal and maternal genetic
scores (GS) for BW in 11,951 babies and 5,182 mothers. These scores capture the direct
fetal and indirect maternal (via intrauterine environment) genetic contributions to BW,
respectively. We also calculated maternal fasting glucose (FG) and systolic blood pressure
(SBP) GS. We tested associations between each GS and probability of SGA or LGA. For
the BW GS, we used simulations to assess evidence of deviation from an expected poly-
genic model.
Higher BW GS were strongly associated with lower odds of SGA and higher odds of LGA
(ORfetal = 0.75 (0.71,0.80) and 1.32 (1.26,1.39); ORmaternal = 0.81 (0.75,0.88) and 1.17
(1.09,1.25), respectively per 1 decile higher GS). We found evidence that the smallest 3% of
babies had a higher BW GS, on average, than expected from their observed birth weight
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Data Availability Statement: We used both
published summary results (i.e. taking results from
published research papers and websites) and
individual participant cohort data as follows:
Journal published and website summary data were
used for generating the genetic scores of birth
weight, fasting glucose and systolic blood
pressure. The references to those published data
sources are provided in the main paper. We used
individual participant data from ALSPAC, EFSOCH
(assuming an additive polygenic model: Pfetal = 0.014, Pmaternal = 0.062). Higher maternal
SBP GS was associated with higher odds of SGA P = 0.005.
We conclude that common genetic variants contribute to risk of SGA and LGA, but that
additional factors become more important for risk of SGA in the smallest 3% of babies.
Author summary
Babies in the lowest or highest 10% of the population distribution of birth weight (BW)
for a given gestational age are referred to as Small- or Large-for-Gestational-Age (SGA or
LGA) respectively. These babies have higher risks of complications compared with babies
with BW closer to the average. SGA and LGA babies may have experienced growth restric-
tion or overgrowth, respectively, but may alternatively just be at the tail ends of the normal
growth distribution. The relative proportions of normal vs. sub-optimal growth within
these groups is unclear. To examine the role of common genetic variation in SGA and
LGA, we tested their associations with a fetal genetic score (GS) for BW in 11,951 Euro-
pean-ancestry individuals. We also tested associations with maternal GS (5,182 mothers)
for offspring BW, fasting glucose and systolic blood pressure, each of which influences
fetal growth via the in utero environment. We found fetal and maternal GS were associ-
ated with SGA and LGA, supporting strong maternal and fetal genetic contributions to
birth weight in both tails of the distribution. However, within the smallest 3% of babies,
the maternal and fetal GS for BW were higher than expected, suggesting factors additional
to common genetic variation are more important in determining birth weight in these
very small babies.
Introduction
Size at birth is an important factor in new-born and infant survival. Term-born babies are
most frequently admitted to the neonatal unit when born at the extremes of the birth weight
distribution [1]. Small for Gestational Age (SGA; defined as birth weight adjusted for sex and
gestational age that is below the 10th percentile of the population or customized standard) is
often used as a proxy indicator of fetal or intrauterine growth restriction (FGR or IUGR [2]).
A fetus is described as growth-restricted when it has failed to reach its growth potential due to
impaired placental function [3] or due to fetal or maternal reasons, and SGA fetuses are at
higher risk of adverse outcomes such as stillbirth [4]. It is likely that SGA infants who are
genetically small are at a lower risk of future morbidity than FGR infants. Risks of adverse out-
comes are increased in preterm babies, and underlying mechanisms in preterm SGA babies
are likely to be different to those born at term. SGA and FGR are often used interchangeably
since fetal growth can be difficult to measure. [2,3] However, they are not synonymous: not all
growth-restricted fetuses are small enough to be considered SGA [5], and the SGA group itself
is heterogeneous with an estimated 50–70% being constitutionally small babies with normal
placental function and outcomes [6], in addition to babies expected to be small due to chromo-
somal anomalies [7].
At the upper end of the birth weight distribution, large for gestational age (LGA, defined as
sex- and gestational age-adjusted birth weight >90th percentile) is associated with a higher risk
of obstructed labour, which can lead to complications for both mother and baby, including
injury, neonatal hypoglycaemia and even fetal death [8]. LGA may indicate excessive growth
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and NFBC cohorts. The data in ALSPAC are fully
available, via managed systems, to any
researchers. The managed system is a requirement
of the study funders but access is not restricted on
the basis of overlap with other applications to use
the data or on the basis of peer review of the
proposed science. Researchers have to pay for a
dataset to be prepared for them. ALSPAC. The
ALSPAC data management plan (http://www.
bristol.ac.uk/alspac/researchers/data-access/
documents/alspac-data-management-plan.pdf)
describes in detail the policy regarding data
sharing, which is through a system of managed
open access. The steps below highlight how to
apply for access to the data included in this paper
and all other ALSPAC data. 1. Please read the
ALSPAC access policy (PDF, 627kB) which
describes the process of accessing the data and
samples in detail, and outlines the costs associated
with doing so. 2. You may also find it useful to
browse the fully searchable ALSPAC research
proposals database, which lists all research
projects that have been approved since April 2011.
3. Please submit your research proposal for
consideration by the ALSPAC Executive
Committee. You will receive a response within 10
working days to advise you whether your proposal
has been approved. If you have any questions
about accessing data, please email alspac-
data@bristol.ac.uk. EFSOCH. Requests for access
to the original EFSOCH dataset should be made in
writing in the first instance to the EFSOCH data
team via the Exeter Clinical Research Facility
crf@exeter.ac.uk. NFBC: Data is available from the
Northern Finland Birth Cohort (NFBC) for
researchers who meet the criteria for accessing
confidential data. Please, contact NFBC project
center (NFBCprojectcenter@oulu.fi) and visit the
cohort website (www.oulu.fi/nfbc) for more
information.
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of the fetus, for example due to elevated maternal glycemia, which is a major determinant of
fetal growth [9]. However, maternal fasting hyperglycemia only explains 2–13% of variation in
birth weight [10,11], and most LGA babies are not born to mothers with diabetes [12]. This
indicates that other factors are also important, for example, many LGA babies may be constitu-
tionally large.
The contribution of common genetic variation to either SGA or LGA is not known, though
associations between LGA and fetal genetic scores for birth weight have been demonstrated
[13,14]. It is possible that a mismatch between a genetic score for birth weight and the actual,
measured birth weight could help to identify babies who have either fallen short of, or
exceeded, their growth potential. In clinical practice, this could be helpful if it improved the
identification of FGR babies among those classified as SGA. Genetic studies of adult height
previously investigated a similar question and showed that a genetic score composed of com-
mon variants was associated with adult height at the extremes of the population distribution
[15]. However, the genetic score was not as extreme as expected in people with very short stat-
ure, suggesting that additional factors (e.g. rare mutations) were more important than com-
mon genetic variation in determining height in that group.
In the current study, we investigated the genetic contribution to SGA and LGA in mothers
and babies of European ancestry, using common genetic variants identified in the most recent
genome wide association study (GWAS) of birth weight [16]. The genetic variants at the 190
most strongly-associated loci have individually small effects, but collectively explain 7% of the
variation in birth weight. These genetic variants have either a direct fetal effect on birth weight
(i.e. those inherited by the fetus and acting via fetal pathways), or an indirect maternal effect
(i.e. through a primary effect on the intrauterine environment), or some combination of the
two (Fig 1). The correlation between maternal and fetal genotypes means that associations
between maternal genotype and birth weight can be confounded by fetal genotype effects, and
vice-versa. To overcome this limitation, Warrington et al [16] estimated the independent
maternal and fetal effect sizes at each of these loci. We used these independent effect sizes to
calculate maternal and fetal genetic scores (GS) for birth weight. These GSs are designed to
capture the independent maternal and fetal genetic contributions to birth weight. We tested
for associations of these GSs with SGA and LGA. We then used simulations to test whether the
GS in the SGA and LGA groups was consistent with an additive polygenic model in which
there are many genetic variants, each contributing a small effect to the phenotype in an addi-
tive manner. Deviation from such a model might be observed if non-additive genetic effects,
rare genetic variants with larger effects, or additional non-genetic factors were contributing to
the risk of SGA or LGA. To investigate further the maternal genetic contribution to intrauter-
ine factors known to be important across the birth weight distribution [16,17], we calculated
genetic scores for fasting glucose (FG) and systolic blood pressure (SBP) and additionally
tested their associations with SGA and LGA.
Methods
Cohort descriptions
Our analysis included a total of 6,769 term-born, singleton individuals with birth weight and
fetal genotype data, from 2 studies, plus 5,182 mother-offspring pairs with maternal and fetal
genotype data and birth weight from 2 further studies. Studies are described below, and sum-
mary data is shown in Table 1.
ALSPAC. The ALSPAC (Avon Longitudinal Study of Parents and Children) is a longitu-
dinal cohort study covering the area of the former county of Avon, UK [18,19]. Women who
were pregnant, living in the study area and had an expected delivery date between 1 April 1991
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and 31 December 1992 were eligible for inclusion in the study. Birth weight and related data
were abstracted from medical records. Children were genotyped on the Illumina Human-
Hap550 chip and mothers were genotyped using the Illumina human660W quad chip. Quality
Control (QC) was undertaken as described previously [16] and imputation was to the HRC
reference panel yielding data available for 8884 mothers and 8860 children with genotype data
available. Of these, 4570 mother-child pairs with phenotype data were available for analysis.
EFSOCH. The Exeter Family Study of Childhood Health (EFSOCH) is a prospective
study of children born between 2000 and 2004 in the Exeter region, UK, and their parents
[20]. Birth weight measurements were performed as soon as possible after delivery. Individuals
were genotyped using the Illumina Infinium HumanCoreExome-24 array. Genotype QC and
imputation have been described previously [13]. After genotype QC, 938 mothers and 712
children with genotype data remained. Of these, 617 mother-child pairs with phenotype data
were available for analysis.
NFBC1966. The Northern Finland Birth Cohort 1966 (NFBC1966) consists of mothers
expected to give birth in the provinces of Oulu and Lapland in 1966 [21]. Birth weight and
related characteristics were measured by examinations occurring directly after birth. Samples
were genotyped on the Infinium 370cnvDuo. QC and imputation to the 1000 genomes
Fig 1. Diagram showing the possible pathways through which parental genotypes can influence birth weight. The black path represents direct fetal genetic effects on
birth weight, and the red path represents maternal genetic factors which have an indirect effect on birth weight by modifying the intrauterine environment. This figure
illustrates that, due to the correlation between maternal and fetal genotypes, genetic association analyses should model both maternal and fetal effects. Other
environmental factors and gene-environment interactions that may influence birth weight are not shown.
https://doi.org/10.1371/journal.pgen.1009191.g001
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reference panel were done centrally, resulting in 5400 children with genotype data. A total of
3691 children with phenotype data were available for analysis.
NFBC1986. The Northern Finland Birth Cohort 1986 (NFBC1986) consists of individu-
als born in the provinces of Oulu and Lapland between 1st July 1985 and 30th June 1986.
Birth weight data was collected from hospital records after delivery. Following genotype
QC, 3742 children with genotype data were available, with 3248 of these having phenotype
data [22].
Table 1. Descriptive statistics of studies contributing to analysis. EFSOCH and ALSPAC sample size is the number of mother-child pairs in the analysis. NFBC1966
and NFBC1986 sample size is the number of offspring in the analysis.
Study ALSPAC EFSOCH NFBC1966 NFBC1986
Country of origin UK UK Finland Finland
Year(s) of birth 1991–1993 2000–2004 1966 1985–6
Sample size (Male /Female
(offspring sex))
4570 (2263/3207) 612 (320/292) 3691 (1839/1852) 3078 (1488/1590)
Data collection Identified from obstetric data, records from the ALSPAC






Mean (SD) birth weight
(grams) Males
3553 (491) 3585 (463) 3607 (506) 3626 (543)
Mean (SD) birth weight
(grams) Females
3423 (450) 3447 (475) 3480 (466) 3519 (521)
Mean (SD) birth weight
(grams)
3490 (476) 3519 (474) 3541 (489) 3572 (535)
Mean Maternal age (SD) 28.0 (4.96) 30.4 (5.28) 27.9 (6.5) 28.0 (5.3)
Mean Maternal Prepregnancy
BMI (SD)
22.9 (3.83) 24.0 (4.45) 23.16 (3.18) 22.33 (3.38)
Median (IQR) GA (weeks) at
delivery
40 (40–41) 40 (39–41) 40 (39–41) 40 (39–40)
Prevalence SGA 7.48% (b) 5.88% (b) 9.90% (c) 5.80% (c)
Prevalence LGA 10.01% (b) 11.60% (b) 11.80% (c) 15.50% (c)


























% First Births 44.90% 49.3% 30.81% 34.0%
Smokers 24.60% 13.0% 19.08% 18.5%
Mean Maternal Height cm
(SD)
164.0 (6.7) 165.0 (6.3) 160.0 (5.3) 163.0 (5.4)
Study description paper
(PMID)
22507742; 22507743 16466435 19060910 31321419
(a) Derived from Office of Population Censuses & Surveys Standard Occupational Classification (Office of Population Censuses and Surveys (1991) Standard
Occupational Classification. Her Majesty’s Stationery Office)
(b) SGA and LGA defined using UK 1990 growth standards [23].
(c) SGA and LGA defined using the Swedish 1991 standards [24].
https://doi.org/10.1371/journal.pgen.1009191.t001
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Phenotype definitions
Since different mechanisms may lead to SGA and LGA in term and preterm infants, and in
multiple births, we focused on term, singleton infants. Birth weight Z scores were calculated
using growth standards separately for each cohort. The UK 1990 growth standards [23], were
used for ALSPAC and EFSOCH and the Swedish 1991 standards [24] were use in NFBC 1966
and 1986 to adjust birth weight for sex and gestational duration. SGA was defined as birth
weight z score< = -1.28, and LGA as birth weight z score > = 1.28. Controls were defined as
those samples with birth weight z score > -1.28 for SGA and birth weight z score< 1.28 for
LGA.
Since the use of growth standards results in different proportions of SGA and LGA by
cohort, we conducted sensitivity analyses for comparison by defining SGA and LGA as the
lower and upper 10% within each cohort. To do this, we regressed birth weight against sex and
gestational age in term births (gestational age> = 37 weeks), and then calculated residuals
from the regression model. Individuals with the smallest and largest 10% within each cohort of
this residualised birth weight variable were defined as SGA and LGA respectively. Controls for
comparison with SGA were taken as birth weight > = 10%, and for comparison with LGA as
birth weight < = 90%. To test the effect of including babies classified as LGA in the control
group for SGA and vice-versa, we conducted sensitivity analysis restricting the control group
for both analyses to 10%< = birth weight< = 90%.
Genetic scores (GS) for birth weight, fasting glucose (FG) and systolic blood pressure (SBP)
were calculated for all included individuals in each cohort, with higher GS corresponding to
higher birth weight, FG or SBP, respectively. GS were calculated using Eq (1) where NSNP is
the total number of SNPs, wi is the weight for SNP i and gi is the genotype at SNP i. The same
SNPs were included in the maternal and fetal GS. To calculate the SNP weightings, wi, since
the cohorts used in our study were included in the largest available GWAS meta-analysis of
birth-weight of Warrington et al [16], we re-ran the maternal and fetal GWAS meta-analyses
of birth weight from that publication, but excluded the ALSPAC, EFSOCH, NFBC1966 and
NFBC1986 studies. We used fixed effects meta-analysis implemented in Metal [25]. We then
adjusted the effect estimates to estimate the independent maternal and fetal effects at each of
the SNPs using the weighted linear model procedure of Warrington et al [16]. These adjusted
effect estimates are designed to capture the independent maternal and fetal contribution at
each SNP, which would otherwise be confounded by the correlation between maternal and
fetal genotype. For the weights in the FG and SBP scores, we used effect estimates reported in
large GWAS of FG and SBP, respectively, and the same weights were used for both maternal
and fetal GS. SNPs and weights used in each score are given in S1–S3 Tables, along with details







Associations between SGA/LGA and maternal or fetal genetic scores for birth weight.
Fetal genotypes (total n = 11,951) were available in ALSPAC (N = 4,570), EFSOCH (N = 612),
NFBC1966 (N = 3,691) and NFBC1986 (N = 3,078). Associations were tested between the fetal
GS for birth weight and outcomes (SGA/LGA) using logistic regression. Maternal genotypes
were also available in ALSPAC (N = 4,570) and EFSOCH (N = 612). In these cohorts, associa-
tions between SGA/LGA and maternal GSs for birth weight were also tested in analogous
regression models. Additional analyses including both maternal and fetal GS in the same
regression model were performed to control for any residual correlation between maternal
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and fetal genotype. Results were meta-analysed using inverse variance weighted meta-analysis
and heterogeneity between studies was assessed using Cochran’s Q test.
Investigating Deviations from the expected Polygenic Model in SGA/LGA. We per-
formed simulations to assess whether there was any evidence of deviation from an expected
additive polygenic model, under which we would not expect additional genetic variation or
non-additive genetic effects in the tails of the birth weight distribution. Briefly, within
ALSPAC and EFSOCH we calculated the associations of each fetal and maternal SNP with
birth weight within each cohort, adjusted for maternal or fetal genotype, respectively. We sim-
ulated genotypes under the allele frequencies observed within each cohort. GSs were calculated
for each simulated individual using simulated genotypes weighted by the within-cohort effect
sizes. Phenotypes were then simulated as
ps ¼ xs þ GSs
where ps is the simulated phenotype for individual s, GSs is the simulated genetic score for
sample s and xs is sampled from a normal distribution




Where s2SNPi is the variance explained by SNP i. The mean GS within each bin of simulated
phenotype was calculated. Simulations were performed 10,000 times to generate a simulated
expected distribution of GS under an additive polygenic model. The observed mean GS was
then compared to the expected distribution and an empirical p value was calculated. These p
values were then meta-analysed.
Bins used in this analysis are 10% and 3% bins. Bin sizes of 3% were chosen because the rates
of adverse outcomes were previously found to be highest in babies below the 3rd centile [27].
Associations between SGA/LGA and maternal genetic scores for fasting glucose or sys-
tolic blood pressure. In ALSPAC and EFSOCH, where maternal genotypes were available,
we tested the associations between the maternal GSs for FG and SBP, with outcomes (SGA/
LGA) using linear regression, including sex and gestational age as covariates to control for
residual confounding. We included both maternal and fetal GS in the same regression model
to control for the correlation between maternal and fetal genotype. Results were meta-analysed
using inverse variance weighted meta-analysis.
Results
Prevalence of SGA and LGA is strongly associated with maternal and fetal
genetic scores for birth weight
The minimum and maximum birth weights in our sample were 970g and 6080g respectively.
The prevalence of SGA and LGA by percentile of fetal or maternal GS in ALSPAC (N = 4,570)
is shown in S1 and S2 Figs, and the mean BW in ALSPAC by percentile of fetal and maternal
GS is shown in S3 Fig. Both the fetal and maternal genetic scores for birth weight showed strong
associations with LGA and SGA (Fig 2, S4A Table) in the expected directions. A one decile
increase in the fetal GS for higher birth weight was associated with a greater odds of LGA
(OR = 1.32 [95%CI: 1.26,1.39]; P = 7.0x10-32) and a lower odds of SGA (OR = 0.75 [0.71,0.80];
P = 8.5x10-21). Similarly, the maternal birth weight-raising GS showed strong associations with
LGA (1.17 [1.09,1.25]; P = 3.2x10-6) and SGA (0.81 [0.75,0.88]; P = 7.7x10-8). Using Cochran’s
Q to test heterogeneity between studies we found no strong evidence of heterogeneity among
studies across all meta-analyses run other than fetal GS for birth weight (unadjusted for mater-
nal genotype) and SGA (P = 0.008). These results were very similar to those of a sensitivity
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analysis of fetal GS conditional on maternal GS (and vice versa) in mother-child pairs (S4B
Table), indicating that the use of the adjusted fetal and maternal weights [15] resulted in fetal
and maternal GSs that were already independent of one another (S4 Table). Results were also
consistent when using Appropriate for Gestational Age (AGA; 10th centile<BW<90th centile)
as the control group, and when LGA and SGA were defined within each cohort as the largest
and smallest 10% of babies, adjusted for sex and gestational age (S5A and S6A Table).
Evidence that the GS in the lowest 3% of the population was higher than
expected
Using simulation analyses in ALSPAC and EFSOCH (N = 5,182) we identified evidence of
deviation from the expected additive polygenic model in the lowest 10% bin of the phenotype
distribution (Pfetal = 0.001, Pmaternal = 0.001). Repeating the analysis using 3% bins showed evi-
dence of deviation in the lowest 3% bin for fetal birth weight GS (P = 0.0142). The maternal
birth weight GS showed strong evidence of deviation in the 3–6% bin (P = 0.002), and weak
evidence of deviation in the lowest 3% bin (P = 0.06; Fig 3; S7 Table). The maternal and fetal
GS for birth weight were higher than expected given the birth weight within these groups, indi-
cating that for a proportion of these babies their birth weight is lower than expected given
their birth weight GS and assuming an additive genetic model. This finding indicates that fac-
tors other than common genetic variants, for example environmental or rare genetic factors,
are acting to reduce birth weight for some individuals in this group.
There was no evidence of deviation from the expected additive polygenic model for the
fetal GS in the top 10% of the phenotype distribution (Pfetal = 0.19). We saw some evidence of
a lower maternal GS than expected in the top 10% group (Pmaternal = 0.0074) but in the top 3%
of the phenotype distribution there was no evidence of deviation (Pmaternal = 0.44), but some
evidence of a lower maternal GS than expected in the 88–91% group (P = 0.018; S7 Table).
Prevalence of SGA and LGA are associated with maternal genetic scores for
fasting glucose and SBP
The maternal GS for higher SBP was associated with higher odds of SGA (1.15 [1.04,1.27];
P = 4.7x10-3) (S8; S5B; S6B Table). This effect, observed across the genetic score distribution, is
Fig 2. Odds of SGA or LGA per 1 decile higher fetal (N = 11,951; ALSPAC, EFSOCH, NFBC1966, NFBC1986) or maternal
(N = 5,181; ALSPAC, EFSOCH) GS for birth weight. Error bars represent 95% confidence intervals, and weights used for fetal and
maternal GS are independent of maternal and fetal effect respectively.
https://doi.org/10.1371/journal.pgen.1009191.g002
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consistent with the known effects of maternal hypertension on birth weight. We found weak
evidence that maternal GS for higher FG was associated with higher odds of LGA (1.06
[0.99,1.14]; P = 0.12) in accordance with the known effect of maternal hyperglycemia, although
the 95%CI was wide and crossed the null. Warrington et al [16] previously demonstrated evi-
dence of causal associations of both maternal FG and SBP with offspring BW across the term
BW range. Since these associations are continuous across the birth weight distribution, our
results show that lower maternal genetic susceptibility to raised SBP is associated with higher
risks of SGA offspring. Associations of maternal SBP GS with LGA (0.93 [0.86–1.01]; P = 0.10)
and FG GS with SGA (0.96 [0.89–1.05]; P = 0.39) were weak and the confidence intervals
included the null (Fig 4, S8 Table). Sensitivity analysis defining SGA and LGA within each
Fig 3. Difference between observed Z statistic for BW Z score (blue line) and simulated mean of birth weight GS (under a fully polygenic model; solid black line) and
simulated upper and lower 95 percentiles (dotted black line) by 3% phenotype bins for fetal GS (left) and maternal GS (right) in ALSPAC.
https://doi.org/10.1371/journal.pgen.1009191.g003
Fig 4. Odds of LGA/SGA 1 per decile higher maternal fasting glucose or SBP GS, corrected for fetal GS in ALSPAC and
EFSOCH (N = 5,182). Error bars represent 95% confidence intervals.
https://doi.org/10.1371/journal.pgen.1009191.g004
PLOS GENETICS Common genetic contributions to SGA and LGA babies
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1009191 December 7, 2020 9 / 15
cohort showed evidence of association of maternal FG GS with LGA (S6A Table) suggesting
that power to detect these associations is low in our sample and, given the known role of
maternal hyperglycemia in LGA risk, which we would expect to be reflected in an association
analysis of maternal FG GS and offspring birth weight, it would be informative to look at these
associations in larger sample sizes.
Discussion
We have shown that common birth weight-associated genetic variation in both the mother
and the fetus contribute to the probability that term infants will be born small or large for ges-
tational age. While these results indicate that a large proportion of those infants classified as
SGA/LGA represent the tail ends of the normal distribution of birth weight, we also found
some evidence of an excess of individuals with a higher GS for increased birth weight than
expected under an additive polygenic model in the bottom 3% of the birth weight distribution.
The terms IUGR and SGA are often used interchangeably [26], which can imply that the
majority of SGA babies have experienced restriction to their intrauterine growth, although it
has been estimated [6] that 50–70% of babies classified as SGA are constitutionally small.
There is a strong association in our study between fetal GS for higher birth weight and lower
SGA risk. Together with the observed deviation from the polygenic model in only the smallest
3% of babies, our results suggest that the majority of babies in the SGA category are constitu-
tionally small, and not growth-restricted. Our results are also consistent with the observation
that the risk of adverse outcomes increases with decreasing birth weight within the SGA
group, and the highest rates of adverse outcomes are in those with birth weight below the 3rd
centile [27].
We observed a higher GS than expected in the bottom 3% of birth weights, indicating that
this group contains a proportion of babies whose birth weights are smaller than would be
expected given their genetics. The demographics of the bottom 3% of individuals are presented
in S9 Table. This group may be enriched for babies whose growth was inhibited by in-utero
environmental factors, such as smoking. However, is it also possible that the presence of rare
mutations with large effects on fetal growth within this group, which are not captured by the
GS, contributed to the observed deviation. This finding would benefit from replication in
larger studies to determine whether the deviation is limited to the smallest 3% of babies.
We found no evidence that the fetal GS for birth weight deviated from the polygenic model
in the top 10% of the birth weight distribution, but there was some evidence of deviation for
the maternal GS in this group. When we looked in smaller 3% bins, however, there was no evi-
dence of association in the top 3% of the distribution. Overall our results do not suggest strong
deviation from the polygenic model in babies with high birth weights, but we cannot rule out
that smaller deviations would be detectable in a larger sample.
Although we have used a population based definition of SGA, customised birth weight stan-
dards including maternal height, weight and ethnic group, for defining SGA have been shown
to increase association between SGA classification and neonatal morbidity and perinatal death
compared to using population based definitions [2], although it has been suggested that this
could be an artefact due to inclusion of more preterm births classified as SGA under this defi-
nition [28]. Babies born preterm have increased risk of neonatal morbidity and mortality com-
pared to term babies, and it is likely that different mechanisms affect growth in preterm babies
compared to IUGR babies born at term. Additionally, individuals classified as SGA by popula-
tion-based growth standards but not by customised standards are not at increased risk of peri-
natal mortality and morbidity compared to those of appropriate weight [29–31]. Including
genetics in the definitions of SGA has the potential to further refine the identification of babies
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who have failed to properly reach their growth potential, as shown by the association between
SGA and birth weight GS demonstrated here.
Fetal genetic effects on birth weight represent the constitutional growth potential of the
fetus, while maternal genetics influence birth weight indirectly by modifying the intrauterine
environment [16]. The strong effects of the maternal GS for birth weight observed in our study
indicate that maternal genetic variation acting via the in utero environment contributes to var-
iation in SGA and LGA risk independently of the fetal genotype. Previous studies have shown
that maternal FG and SBP have causal effects on birth weight in the normal range [15,16]. In
women at highest genetic risk for raised FG and SBP, these could potentially contribute to
LGA and SGA, respectively. We therefore investigated the associations between maternal
genetic scores for FG or SBP and the risk of SGA or LGA. In line with known consequences of
maternal gestational hypertension, a higher maternal SBP GS increased odds of SGA. The
association of a 1 decile higher maternal SBP GS (OR = 1.15) is substantial in comparison to
the effect of maternal hypertension on odds of SGA (OR = 1.35 [32]). A higher maternal FG
GS showed weak evidence of association with higher odds of LGA in accordance with the
known effects of maternal gestational diabetes, although the confidence intervals were wide.
Given the known association between maternal gestational diabetes and LGA, replication in
larger studies will be necessary to determine the potential contribution of lower maternal fast-
ing glucose to SGA risk.
The current study has a number of strengths and limitations. Strengths include the fact that
we have been able to construct independent maternal and fetal GS for birth weight. Separating
maternal and fetal genetic contributions to birth weight is important because maternal and
fetal genotype are correlated. This means that to avoid confounding, it is necessary to account
for this correlation and obtain independent estimates of maternal and fetal genetic effects. To
construct the GSs we chose to use only SNPs associated with the exposure (birth weight, SBP
and FG) at a genome-wide threshold in their discovery samples. This decision ensures that the
SNPs are robustly associated with the exposure and unlikely to also capture pleiotropic associa-
tions with other correlated phenotypes. In addition, the relationship between maternal and
fetal genotype causes difficulty in estimating independent maternal and fetal genetic associa-
tions at each SNP. Limiting the SNPs to those with good power to estimate these independent
associations improves the separation of maternal and fetal effects of the GSs. Both a limitation
and strength of our study is that all of the cohorts used were of European ancestry. The GSs
used in this study were discovered in studies of European ancestry and generalisability to stud-
ies of non-European ancestry has not been widely tested. In addition, well powered cohorts of
mother-child pairs with genotype data as well as birth weight data are not currently available,
meaning that the conclusions of the present study are not necessarily generalisable to individu-
als of non-European ancestry. As such there is a need for genetic studies in populations of
ancestries other than Europeans. The use of only singleton, term babies in our analysis means
that our results do not necessarily translate to pre-term babies or multiple births. While we
had sufficient sample size to estimate the association of birth weight GS with SGA/LGA, the
limited number of mother-child pairs which were available to examine the associations of FG
and SBP GS with SGA/LGA meant that these estimates had large confidence intervals. Larger
numbers of mother-child pairs would allow for more precise estimates, for example of the
association of low SBP on LGA which has potentially clinically relevant implications. Although
SGA and FGR are often used synonymously, there are differences between the terms. In our
study do not have information required to distinguish FGR babies from SGA ones, meaning
that we were not able to examine the association between BW GS and FGR specifically.
Our analysis has shown that common birth weight-associated genetic variation contributes
to the risk of babies being born small or large for gestational age. We found evidence of
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deviation from the polygenic model in the smallest 3% of babies, consistent with enrichment
for fetal growth restriction in this group.
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S1 Fig. Fraction of babies born SGA (left) or LGA (right) by percentile bins of fetal birth
weight GS in ALSPAC (N = 4,569).
(PNG)
S2 Fig. Fraction of babies born SGA (left) or LGA (right) by percentile bins of maternal birth
weight GS in ALSPAC (N = 4,569).
(PNG)
S3 Fig. Mean birth weight in ALSPAC by percentile bins of fetal (left) and maternal (right)
birth weight GS (N = 4,569).
(PNG)
S1 Table. SNPs and weights used to construct fetal and maternal birth weight GS. Source
PMID:31043758.
(XLSX)
S2 Table. SNPs and weights used to construct fasting glucose GS.
(XLSX)
S3 Table. SNPs and weights used to construct SBP GS.
(XLSX)
S4 Table. A) Associations between fetal and maternal birth weight GS and LGA/SGA. Fetal
GS associations include ALSPAC, EFSOCH, NFBC86 and NFBC66. Maternal GS associations
include ALSPAC and EFSOCH. Odds ratios represent the increase in risk per decile of birth
weight GS. B) Associations between fetal and maternal BW GS and LGA/SGA, adjusted for
maternal and fetal BW GS respectively in ALSPAC and EFSOCH mother-child pairs.
(XLSX)
S5 Table. A) Associations between Fetal and Maternal BW GS and LGA/SGA. The control
group consists of babies with birth weight >10th centile and<90th centile. Odds ratios repre-
sent the increase in risk per decile of BW GS. B) Associations between Maternal FG and SBP
GS, adjusted for fetal genotype, and LGA/SGA. The control group consists of babies with birth
weight >10th centile and<90th centile. Odds ratios represent the increase in risk per decile of
FG/SBP GS.
(XLSX)
S6 Table. A) Associations between Fetal and Maternal BW GS and LGA/SGA defined within
each cohort. Odds ratios represent the increase in risk per decile of BW GS. B) Associations
between Maternal FG and SBP GS, adjusted for fetal genotype, and LGA/SGA defined within
each cohort. Odds ratios represent the increase in risk per decile of FG/SBP GS.
(XLSX)
S7 Table. Results from meta-analysis of simulations in ALSPAC and EFSOCH to analyse
deviations from the expected polygenic model.
(XLSX)
S8 Table. Associations between Maternal FG and SBP GS and LGA/SGA, with adjustment
for fetal GS un ALSPAC and EFSOCH mother-child pairs. Associations include mother-
child pairs from ALSPAC and EFSOCH. Odds ratios represent the increase in risk per decile
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